- Home
- SCLX vs NIM Comparison
SCLX vs NIM Comparison
Compare SCLX & NIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- NIM
- Stock Information
- Founded
- SCLX 2011
- NIM 1992
- Country
- SCLX United States
- NIM United States
- Employees
- SCLX N/A
- NIM N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- NIM Trusts Except Educational Religious and Charitable
- Sector
- SCLX Health Care
- NIM Finance
- Exchange
- SCLX Nasdaq
- NIM Nasdaq
- Market Cap
- SCLX 130.1M
- NIM 115.9M
- IPO Year
- SCLX N/A
- NIM N/A
- Fundamental
- Price
- SCLX $0.61
- NIM $8.99
- Analyst Decision
- SCLX Strong Buy
- NIM
- Analyst Count
- SCLX 3
- NIM 0
- Target Price
- SCLX $11.33
- NIM N/A
- AVG Volume (30 Days)
- SCLX 184.3K
- NIM 35.4K
- Earning Date
- SCLX 11-26-2024
- NIM 01-01-0001
- Dividend Yield
- SCLX N/A
- NIM 3.46%
- EPS Growth
- SCLX N/A
- NIM N/A
- EPS
- SCLX N/A
- NIM N/A
- Revenue
- SCLX $50,833,000.00
- NIM N/A
- Revenue This Year
- SCLX $32.77
- NIM N/A
- Revenue Next Year
- SCLX $50.71
- NIM N/A
- P/E Ratio
- SCLX N/A
- NIM N/A
- Revenue Growth
- SCLX 9.41
- NIM N/A
- 52 Week Low
- SCLX $0.54
- NIM $8.28
- 52 Week High
- SCLX $2.63
- NIM $9.74
- Technical
- Relative Strength Index (RSI)
- SCLX 28.71
- NIM 37.36
- Support Level
- SCLX $0.73
- NIM $8.96
- Resistance Level
- SCLX $1.14
- NIM $9.15
- Average True Range (ATR)
- SCLX 0.11
- NIM 0.08
- MACD
- SCLX -0.04
- NIM -0.00
- Stochastic Oscillator
- SCLX 11.99
- NIM 15.80
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About NIM Nuveen Select Maturities Municipal Fund
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital by investing in an investment-grade quality portfolio of municipal obligations with intermediate characteristics.